Tracking therapeutic T cells in vivo

Area of Science:

• Biotechnology
• Immunotherapy
• Medical Imaging

Background:

• Engineered cell therapies, including chimeric antigen receptor (CAR) T-cell therapies, show significant promise for treating cancers and autoimmune diseases.
• Seven CAR T-cell therapies are FDA-approved as of 2025, highlighting rapid advancements in the field.
• A critical knowledge gap exists regarding the in vivo behavior of adoptively transferred cells.

Purpose of the Study:

• To emphasize the importance of noninvasive methods for monitoring engineered T-cell dynamics in real time.
• To highlight the role of imaging in assessing T-cell persistence, proliferation, functionality, and distribution.
• To guide improvements in engineered cell therapy development and clinical treatment strategies.

Main Methods:

• Discussing cell tracking and labeling strategies for engineered T-cell therapies.
• Exploring molecular imaging techniques for noninvasive, whole-body cell monitoring.
• Reviewing approaches compatible with therapeutic cell proliferation and persistence.

Main Results:

• Molecular imaging enables noninvasive, long-term monitoring of adoptively transferred cells.
• Imaging can assess key parameters like persistence, proliferation, functionality, and distribution.
• These methods aid in real-time patient response assessment and therapy optimization.

Conclusions:

• Noninvasive monitoring is essential for advancing engineered T-cell therapies.
• Molecular imaging provides a powerful tool for tracking cell dynamics in vivo.
• Optimized tracking strategies will improve therapeutic efficacy and clinical application.